



March 6, 2018

Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting

BEDFORD, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- [Anika Therapeutics, Inc.](#) (NASDAQ:ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary [hyaluronic acid \("HA"\) technology](#), today announced plans to showcase its innovative commercial and pipeline portfolio at the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, being held in New Orleans on March 6 - 10, 2018. Anika's appearance at the world's largest meeting of orthopedic surgeons, researchers and allied health professionals, will feature an educational workshop on HYALOFAST[®] and product and technology demonstrations at its AAOS exhibit booth #6933.

"We're excited to attend the 2018 AAOS Annual Meeting to showcase our expansive orthopedic product portfolio, and proprietary HA-based technologies which fuel our thriving R&D pipeline," said Joseph Darling, President and newly named CEO of Anika Therapeutics. "AAOS coincides with a transformational time for Anika as we build our direct commercialization operations to support the launch of our innovative combination viscosupplement, CINGAL[®], and accelerate our clinical development and R&D efforts to yield a series of commercial, regulatory and clinical milestones over the next 12 to 18 months. We look forward to introducing Anika and its portfolio to the 30,000-plus members of the global orthopedic surgery community at AAOS, and forging relationships with key stakeholders who will be critical to the success of our direct sales and marketing efforts."

Below are highlights of Anika's planned activities at the 2018 AAOS Annual Meeting:

- ┆ Anika Exhibit Booth #6933
- ┆ Bioskills Workshop on HYALOFAST, Wednesday, March 7th from 5:30-8:30 p.m. in Lab 3 at the AAOS Conference Center. This workshop is open to all registered AAOS Meeting attendees.

"Our participation in the 2018 AAOS Annual Meeting represents an important opportunity for Anika to engage U.S. orthopedic medicine thought-leaders about CINGAL, and showcase both real-world evidence from its successful launches overseas and clinical evidence from the first CINGAL Phase III study, to validate its benefits and advantages over currently available single-agent viscosupplements," said Joseph Darling.

About Anika Therapeutics, Inc.

[Anika Therapeutics, Inc.](#) (NASDAQ:ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary [hyaluronic acid \(HA\) technology](#). Anika's orthopedic medicine portfolio includes [ORTHOVISC[®]](#), [MONOVISC[®]](#), and [CINGAL](#), which alleviate pain and restore joint function by replenishing depleted HA, and [HYALOFAST](#), a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer	For Media Inquiries: Pure Communications Sonal Vasudev, 917-523-1418, sonal@purecommunicationsinc.com
---	---

Primary Logo

Source: Anika Therapeutics Inc.

News Provided by Acquire Media